MilliporeSigma has launched its newest high-sensitivity detection platform, SMCxPRO technology. It is designed to allow researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design. It will be available in the third quarter this year.

“MilliporeSigma’s newest innovation, SMCxPRO technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity,” said Jason Apter, head of research solutions strategic marketing and innovation, MilliporeSigma. “Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare.”

Along with the new SMCxPRO technology, MilliporeSigma offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company’s suite of gene editing tools.